---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-24-000096"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:23:09.790645+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on

## Summary
- Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.
- Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.
- VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.
- VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.
- VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025.

## SEC filing metadata
- accession: 0001649094-24-000096
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/0001649094-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/pcvx-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-24-000096
- JSON: https://secwatch.observer/filing/0001649094-24-000096.json
- Plain text: https://secwatch.observer/filing/0001649094-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.